Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease

Movement Disorders

Volumn 30, Issue 9, 2015, Pages 1229-1236

  Zhang, Yu ^a,b   Wu, I Wei ^a,b   Buckley, Shannon ^a,b   Coffey, Christopher S ^c   Foster, Eric ^c   Mendick, Susan ^d   Seibyl, John ^d   Schuff, Norbert ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

Author keywords

diffusion tensor imaging; diffusion tensor tractography; MRI; nigrostriatal pathway; Parkinson's disease

Indexed keywords

AGED; ANISOTROPY; CORPUS STRIATUM; DIFFUSION TENSOR IMAGING; FEMALE; HUMAN; IMAGE PROCESSING; MALE; MIDDLE AGED; NERVE TRACT; PARKINSON DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; SUBSTANTIA NIGRA PARS COMPACTA;

AGED; ANISOTROPY; CORPUS STRIATUM; DIFFUSION TENSOR IMAGING; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEURAL PATHWAYS; PARKINSON DISEASE; PARS COMPACTA; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 85018214938     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26251     Document Type: Article

References (39)

1. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366–375.
2. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281–285.
3. Pierpaoli C, Jezzard P, Basser PJ, Barnett A, Di Chiro G. Diffusion tensor MR imaging of the human brain. Radiology 1996;201:637–648.
4. Beaulieu C. The basis of anisotropic water diffusion in the nervous system: a technical review. NMR Biomed 2002;15:435–455.
5. Cochrane CJ, Ebmeier KP. Diffusion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis. Neurology 2013;80:857–864.
6. Ofori E, Pasternak O, Planetta PJ, et al. Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study. Neurobiol Aging 2015;36:1097–1104.
7. Mori S, van Zijl PC. Fiber tracking: principles and strategies—a technical review. NMR Biomed 2002;15:468–480.
8. Lehéricy S, Ducros M, Krainik A, et al. Diffusion tensor fiber tracking shows distinct corticostriatal circuits in humans. Cereb Cortex 2004;14:1302–1309.
9. Basser PJ, Pajevic S, Pierpaoli C, Duda J, Aldroubi A. In vivo fiber tractography using DT-MRI data. Magn Reson Med 2000;44:625–632.
10. Menke RA, Scholz J, Miller KL, Deoni S, Jbabdi S, Matthews PM, Zarei M. MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study. Neuroimage 2009;47:435–441.
11. Sharman M, Valabregue R, Perlbarg V, et al. Parkinson's disease patients show reduced cortical-subcortical sensorimotor connectivity. Mov Disord 2013;28:447–454.
12. Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011;95:629–635.
13. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129–2170.
14. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–442.
15. Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord 2001;16:1023–1032.
16. Schuff N, Wu K, Buckley S, et al. Diffusion tensor imaging of nigral alterations in early Parkinson's disease with dopamine deficits. Mov Disord (in press 2014).
17. Rohde GK, Barnett AS, Basser PJ, Pierpaoli C. Estimating intensity variance due to noise in registered images: applications to diffusion tensor MRI. Neuroimage 2005;26:673–684.
18. Wedeen VJ, Wang RP, Schmahmann JD, et al. Diffusion spectrum magnetic resonance imaging (DSI) tractography of crossing fibers. Neuroimage 2008;41:1267–1277.
19. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979;86:420–428.
20. Lebedev AV, Westman E, Simmons A, Lebedeva A, Siepel FJ, Pereira JB, Aarsland D. Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits. Front Syst Neurosci 2014 3;8:45.
21. Smith Y, Shink E, Sidibé M. Neuronal circuitry and synaptic connectivity of the basal ganglia. Neurosurg Clin North Am 1998;9:203–222.
22. Tsui A, Isacson O. Functions of the nigrostriatal dopaminergic synapse and the use of neurotransplantation in Parkinson's disease. J Neurol 2011;258:1393–1405.
23. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415–455.
24. Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr 1960;38:1236–1239.
25. Lindvall O, Björklund A. Cell therapeutics in Parkinson's disease. Neurotherapeutics 2011;8:539–548.
26. Pogarell O, Koch W, Gildehaus FJ, Kupsch A, Lindvall O, Oertel WH, Tatsch K. Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. Eur J Nucl Med Mol Imaging 2006;33:407–411.
27. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003;9:589–595.
28. Manfredsson FP, Okun MS, Mandel RJ. Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson's disease. Neurobiol Dis 2007;25:35–44.
29. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 2005;102:216–222.
30. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009;72:1378–1384.
31. Pasternak O, Westin CF, Bouix S, et al. Excessive extracellular volume reveals a neurodegenerative pattern in schizophrenia onset. J Neurosci 2012;32:17365–17372.
32. Zhao YJ, Wee HL, Au WL, et al. Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times. Parkinsonism Relat Disord 2011;17:194–197.
33. The Parkinson Progression Marker Initiative (PPMI). The Parkinson's progression marker initiative (PPMI): assessment of clinical, imaging and CSF PD biomarkers. Mov Disord 2014;29(Suppl 1):729.
34. Chan LL, Rumpel H, Yap K, et al. Case control study of diffusion tensor imaging in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:1383–1386.
35. Prakash BD, Sitoh YY, Tan LC, Au WL. Asymmetrical diffusion tensor imaging indices of the rostral substantia nigra in Parkinson's disease. Parkinsonism Relat Disord 2012;18:1029–1033.
36. Zhang K, Yu C, Zhang Y, Wu X, Zhu C, Chan P, Li K. Voxel-based analysis of diffusion tensor indices in the brain in patients with Parkinson's disease. Eur J Radiol 2011;77:269–273.
37. Karimi M, Tian L, Brown CA, et al. Validation of nigrostriatal positron emission tomography measures: critical limits. Ann Neurol 2013;73:390–396.
38. Wedeen VJ, Hagmann P, Tseng WY, Reese TG, Weisskoff RM. Mapping complex tissue architecture with diffusion spectrum magnetic resonance imaging. Magn Reson Med 2005;54:1377–1386.
39. Tuch DS, Reese TG, Wiegell MR, Makris N, Belliveau JW, Wedeen VJ. High angular resolution diffusion imaging reveals intravoxel white matter fiber heterogeneity. Magn Reson Med 2002;48:577–582.